| Primary |
| Drug Use For Unknown Indication |
22.4% |
| Product Used For Unknown Indication |
13.7% |
| Acute Coronary Syndrome |
12.3% |
| Stent Placement |
6.7% |
| Hypertension |
6.4% |
| Prophylaxis |
4.6% |
| Angina Unstable |
4.3% |
| Antiplatelet Therapy |
3.9% |
| Atrial Fibrillation |
3.3% |
| Diabetes Mellitus |
3.3% |
| Percutaneous Coronary Intervention |
3.2% |
| Thrombosis Prophylaxis |
2.5% |
| Angina Pectoris |
2.3% |
| Coronary Artery Disease |
2.2% |
| Myocardial Infarction |
1.9% |
| Constipation |
1.6% |
| Acute Myocardial Infarction |
1.5% |
| Anticoagulant Therapy |
1.4% |
| Type 2 Diabetes Mellitus |
1.3% |
| Transient Ischaemic Attack |
1.1% |
|
| Death |
8.2% |
| Cardiac Failure |
6.6% |
| In-stent Coronary Artery Restenosis |
6.6% |
| Vomiting |
6.6% |
| Thrombosis In Device |
6.1% |
| Anaemia |
5.6% |
| Dyspnoea |
5.6% |
| Myocardial Infarction |
5.6% |
| Syncope |
5.6% |
| Pyrexia |
5.1% |
| Transient Ischaemic Attack |
5.1% |
| Vascular Pseudoaneurysm |
5.1% |
| Vertigo |
4.6% |
| Rectal Haemorrhage |
4.1% |
| Pericardial Effusion |
3.6% |
| Pneumonia |
3.6% |
| Coronary Artery Restenosis |
3.1% |
| Gastrointestinal Haemorrhage |
3.1% |
| Haemoglobin Decreased |
3.1% |
| Off Label Use |
3.1% |
|
| Secondary |
| Hypertension |
12.0% |
| Drug Use For Unknown Indication |
9.3% |
| Product Used For Unknown Indication |
8.3% |
| Acute Coronary Syndrome |
8.1% |
| Stent Placement |
7.9% |
| Prophylaxis |
7.2% |
| Antiplatelet Therapy |
5.3% |
| Angina Unstable |
5.1% |
| Angina Pectoris |
4.8% |
| Percutaneous Coronary Intervention |
4.3% |
| Coronary Artery Disease |
4.1% |
| Diabetes Mellitus |
3.8% |
| Acute Myocardial Infarction |
3.7% |
| Myocardial Infarction |
2.8% |
| Type 2 Diabetes Mellitus |
2.5% |
| Thrombosis Prophylaxis |
2.5% |
| Coronary Arterial Stent Insertion |
2.4% |
| Prophylaxis Against Renal Transplant Rejection |
2.2% |
| Anticoagulant Therapy |
1.9% |
| Atrial Fibrillation |
1.8% |
|
| Thrombosis In Device |
12.1% |
| Pericardial Effusion |
9.8% |
| Myocardial Infarction |
7.5% |
| In-stent Coronary Artery Restenosis |
6.8% |
| Rectal Haemorrhage |
6.5% |
| Vomiting |
6.5% |
| Subdural Haematoma |
5.5% |
| Gastrointestinal Haemorrhage |
4.9% |
| Overdose |
4.2% |
| Rhabdomyolysis |
4.2% |
| Upper Gastrointestinal Haemorrhage |
4.2% |
| Vision Blurred |
3.6% |
| Cardiac Failure |
3.3% |
| Vascular Pseudoaneurysm |
3.3% |
| Acute Myocardial Infarction |
2.9% |
| Haematuria |
2.9% |
| Renal Failure |
2.9% |
| Rheumatoid Arthritis |
2.9% |
| Thrombocytopenia |
2.9% |
| Ventricular Fibrillation |
2.9% |
|
| Concomitant |
| Drug Use For Unknown Indication |
26.1% |
| Product Used For Unknown Indication |
17.9% |
| Hypertension |
11.0% |
| Diabetes Mellitus |
4.6% |
| Hiv Infection |
4.6% |
| Coronary Artery Disease |
4.4% |
| Type 2 Diabetes Mellitus |
4.1% |
| Hypercholesterolaemia |
3.5% |
| Pain |
3.0% |
| Rheumatoid Arthritis |
3.0% |
| Thrombosis Prophylaxis |
2.4% |
| Acute Coronary Syndrome |
2.2% |
| Myocardial Infarction |
2.1% |
| Cardiac Disorder |
2.1% |
| Myocardial Ischaemia |
1.8% |
| Multiple Myeloma |
1.6% |
| Depression |
1.5% |
| Hyperlipidaemia |
1.4% |
| Acute Myocardial Infarction |
1.3% |
| Hyperparathyroidism Secondary |
1.3% |
|
| Rhabdomyolysis |
14.1% |
| Myocardial Infarction |
12.7% |
| Renal Failure Acute |
8.5% |
| Thrombocytopenia |
8.3% |
| Vomiting |
7.5% |
| Pyrexia |
4.6% |
| Nausea |
4.4% |
| Death |
4.2% |
| Myalgia |
4.1% |
| Syncope |
3.6% |
| Weight Decreased |
3.6% |
| Pain In Extremity |
3.2% |
| Cerebrovascular Accident |
3.1% |
| Urinary Tract Infection |
3.1% |
| Pneumonia |
2.9% |
| Renal Failure |
2.9% |
| Acute Myocardial Infarction |
2.5% |
| Drug Interaction |
2.4% |
| Ventricular Tachycardia |
2.4% |
| Tuberculosis |
2.2% |
|
| Interacting |
| Myocardial Infarction |
29.6% |
| Product Used For Unknown Indication |
21.3% |
| Chalazion |
8.3% |
| Antibiotic Therapy |
4.6% |
| Antiplatelet Therapy |
3.7% |
| Chest Pain |
3.7% |
| Pulmonary Embolism |
3.7% |
| Trigeminal Neuralgia |
3.7% |
| Acute Myocardial Infarction |
2.8% |
| Cellulitis |
2.8% |
| Coronary Artery Stenosis |
1.9% |
| Pain |
1.9% |
| Percutaneous Coronary Intervention |
1.9% |
| Pneumonia |
1.9% |
| Smoking Cessation Therapy |
1.9% |
| Stent Placement |
1.9% |
| Ventricular Tachycardia |
1.9% |
| Angina Pectoris |
0.9% |
| Atrial Fibrillation |
0.9% |
| Cerebrovascular Accident Prophylaxis |
0.9% |
|
| Acute Myocardial Infarction |
12.5% |
| Intraocular Pressure Increased |
12.5% |
| Drug Ineffective |
8.3% |
| Drug Interaction |
8.3% |
| Myocardial Infarction |
8.3% |
| Pneumocystis Jiroveci Pneumonia |
8.3% |
| Drug Effect Decreased |
4.2% |
| Haemorrhage |
4.2% |
| Haemorrhage Intracranial |
4.2% |
| Hallucination |
4.2% |
| Leiomyoma |
4.2% |
| Nausea |
4.2% |
| Pulmonary Alveolar Haemorrhage |
4.2% |
| Retroperitoneal Haematoma |
4.2% |
| Upper Gastrointestinal Haemorrhage |
4.2% |
| Urine Output Decreased |
4.2% |
|
